lns8801
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Oct 21, 2019 (NCT04130516)
Timeline
Indications
Mechanism of action
GPER1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06624644 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2024 | Linnaeus Therapeutics, Inc., Merck |
| NCT04130516 | Phase 1 | Oct 21, 2019 | Linnaeus Therapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Linnaeus Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1